Avoid common mistakes on your manuscript.
Correction to: Cancer Immunology, Immunotherapy (2023) 72:3839–3850 https://doi.org/10.1007/s00262-023-03539-8
The original version of this article unfortunately contained a mistake. The corrected detail is provided below:
In discussion section, 6th sentence of the 10th paragraph which previously read:
In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit extended duration of treatment with RFD.
Should read:
In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit from extended duration of treatment with RFD.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Tachiki, L.M.L., Hippe, D.S., Silva, K.W. et al. Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma. Cancer Immunol Immunother 72, 4471 (2023). https://doi.org/10.1007/s00262-023-03575-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-023-03575-4